Abtastung

European patent · EP2573563 · In force

Register entry

Publication number
EP2573563
Application number
EP12192130
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Dec 19, 2008
Published
Mar 27, 2013
Granted
Dec 25, 2024
Protection ends at the latest
Dec 18, 2028
Next annual fee due
Dec 31, 2026
IPC classes
G01N 33/566 (2006.01)
C07K 14/705 (2006.01)
C12N 15/10 (2006.01)
G01N 33/543 (2006.01)
Priority
GB 0724860 20.12.2007
Divided from
EP08865061
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Jan 1, 2026

    Change

    Published in Swissreg on 01.01.2026

  2. Nov 5, 2025

    Change

    Published in Swissreg on 05.11.2025

  3. Dec 27, 2024

    Agent entered

    Representative
    Bovard SA, Optingenstrasse 16, 3013 Bern

    Published in Swissreg on 27.12.2024

  4. Dec 25, 2024

    Granted

    Specification status
    Non-published patent application → Granted patent
    Status of protective title
    Initiated → Active

    Published in Swissreg on 25.12.2024

Parties

Holder

Nxera Pharma UK Limited

Granta Park Great Abington, Cambridge, Cambridgeshire CB21 6DG, GB

Agent

Bovard AG

Bovard SA

Optingenstrasse 16, 3013 Bern

Inventor

Weir, Malcolm Peter

Cambridge CB21 6DG, GB

Marshall, Fiona Hamilton

Cambridge CB21 6DG, GB

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.